Argentine authorities have permanently shut down Laboratorios Ramallo and HLB Pharma following the discovery of multi-resistant bacteria in fentanyl ampoules [2].
The case highlights critical failures in pharmaceutical manufacturing and regulatory oversight that resulted in patient deaths. It has sparked a national investigation into the safety of the drug supply chain and the efficacy of government surveillance.
The contamination occurred throughout 2025 [2], with the drug being administered to patients in various medical settings. The first nine deaths were identified at the Hospital Italiano de La Plata [1]. While those nine cases are confirmed, investigators have expressed doubts regarding the total number of victims, suggesting a potential "black figure" of deaths that remains uncounted [3].
Investigations revealed that both Laboratorios Ramallo and HLB Pharma had a history of complaints regarding poor manufacturing practices [3]. These failures allowed bacteria to contaminate the ampoules, leading to fatal infections in patients receiving the medication. In response to the crisis, the National Administration of Drugs, Food and Medical Technology (ANMAT) fired Mariela Andrea García, the director responsible for post-marketing surveillance [3].
Families of the victims have spoken out about the tragedy as the one-year anniversary of the events arrived on May 13 [3]. The daughter of one of the first victims described the loss of her father as a killing, stating, "A mi papá lo mataron" [2].
In addition to the laboratory closures, the General Audit Office (AGN) decided to audit the safety alert systems of ANMAT to determine how the contamination persisted despite reports of poor practices [3]. The criminal investigation continues to determine the full scope of the negligence, and the exact number of fatalities caused by the adulterated drug [3].
“"A mi papá lo mataron"”
This incident exposes a systemic failure in Argentina's pharmaceutical oversight, where known manufacturing deficiencies at two laboratories were not corrected before causing patient deaths. The removal of a high-ranking ANMAT official and the subsequent audit by the AGN suggest that the crisis was not merely a technical failure of sterilization, but a regulatory failure in monitoring and responding to safety alerts.
